We are a clinical-stage oncology company led by a world-class senior management team of proven oncology drug developers. Our vision is to be a leader in developing and commercializing a board and diverse portfolio of cancer therapies that deliver therapeutic outcomes that dramatically change patients’ lives.
Our lead DNAi product candidate, PNT2258, is based on our proprietary DNA interference (DNAi) technology platform. PNT2258 is designed to target BCL2, a widely overexpressed oncogene that is an important gatekeeper of the programmed cell death process known as apoptosis and has been linked to many forms of cancer. We are pursuing a multi-faceted clinical development strategy that is designed to efficiently achieve regulatory approval and maximize the commercial opportunity of PNT2258. Currently, we are enrolling patients in Wolverine, a Phase 2 trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma, and in Brighton, a Phase 2 trial evaluating PNT2258 for the treatment of Richter’s transformation.